Treatment of lacrimal gland adenoid cystic carcinoma: a systematic review and Meta-analysis

• Published in: International journal of ophthalmology Vol. 17; no. 1; pp. 164 - 172
• Main Authors: Yan, Hai-Han, Liu, Rui, Wang, Nan, Xu, Liang-Yuan, Guo, Qi-Han, Li, Jing, Ma, Jian-Min
• Format: Journal Article
• Language: English
• Published: China International Journal of Ophthalmology Press 18.01.2024; Press of International Journal of Ophthalmology (IJO PRESS)
• Subjects: adenoid cystic carcinoma; lacrimal gland; Meta-Analysis; adenoid cystic carcinoma; lacrimal gland; Meta-analysis
• ISSN: 2222-3959; 2227-4898
• DOI: 10.18240/ijo.2024.01.22

To evaluate lacrimal gland adenoid cystic carcinoma (LGACC) of prognosis in patients who underwent different treatment regimens. We searched PubMed, EMBASE, and the Cochrane Library for studies done on the treatment of LGACC, between January 1987 and April 2022. A Meta-analysis was conducted to pool the 5-year overall survival rate (OR), and the 5-year recurrence rate (RR) and 5-year metastasis rate (MR) were assessed. The 30 studies involved 585 patients were included in the Meta-analysis. The pooled 5-year OR with surgery alone was 50%, the 5-year RR was 63%, and the 5-year MR was 34%. The pooled 5-year OR with surgery and adjuvant radiotherapy combined was 67% (95%CI 61%,73%), the 5-year RR was 41%, and the 5-year MR was 35%. The pooled 5-year OR with surgery and adjuvant chemoradiotherapy combined was 72% (95%CI 59%, 84%), the 5-year RR was 48%, and the 5-year MR was 36%. The pooled 5-year OR with surgery, intra-arterial cytoreductive chemotherapy, and adjuvant chemoradiotherapy combined was 78% (95%CI 68%, 89%), the 5-year RR was 15%, and the 5-year MR was 27%. Comprehensive treatment is more effective than surgery alone. Surgery combined with intra-arterial chemotherapy and adjuvant chemoradiotherapy seems to add value to the therapeutic effect of comprehensive treatment of LGACC but further high-quality research is required to validate this.